secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001558370-24-011808
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics reports Q2 2024 net loss of $3.5M; Phase 1 trial initiated for APR-1051
--------------------------------------------------------------------------------

- Cash $28.7M as of June 30, 2024, up from $21.6M at Dec 31, 2023; runway extended into Q4 2025.
- Net loss $3.5M ($0.58 per share) vs $3.3M ($0.87) in Q2 2023; operating loss $3.8M.
- Enrollment commenced in Phase 1 ACESOT-1051 trial of APR-1051 (WEE1 inhibitor); no myelosuppression in first cohort.
- ABOYA-119 Phase 1/2a trial of ATRN-119 (ATR inhibitor) continues; first five dose cohorts completed; Phase 1 readout expected 1H 2025.
- Appointed Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer effective May 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024011808/0001558370-24-011808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024011808/apre-20240812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer